Scholar Rock Holding (SRRK) Change in Acquisitions & Divestments (2017 - 2026)

Scholar Rock Holding's (SRRK) quarterly Change in Acquisitions & Divestments came in at $20.0 million in Q1 2026, down 78.47% year-on-year from $92.9 million in Q1 2025, and down 48.72% quarter-over-quarter from $39.0 million in Q4 2025.

Scholar Rock Holding (SRRK) Change in Acquisitions & Divestments (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Change in Acquisitions & Divestments history runs 10 years deep, the most recent figure standing at $20.0 million for Q1 2026.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 78.47% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $244.4 million, a 1.12% increase from a year earlier, with the FY2025 full-year figure at $317.3 million, up 46.09% from the prior year.
  • Change in Acquisitions & Divestments declined to $20.0 million in Q1 2026 per SRRK's latest filing, from $39.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $106.9 million in Q2 2025 and bottomed at $10.0 million in Q1 2022.
  • The 5-year median for Change in Acquisitions & Divestments is $68.4 million (2024), against an average of $59.8 million.
  • Across the five-year window, Change in Acquisitions & Divestments plunged 81.82% in 2022 and jumped 800.0% in 2023, its largest moves.
  • Year by year, Change in Acquisitions & Divestments stood at $10.0 million in 2022, then soared by 690.0% to $79.0 million in 2023, then slumped by 80.89% to $15.1 million in 2024, then soared by 158.28% to $39.0 million in 2025, then slumped by 48.72% to $20.0 million in 2026.
  • Per Business Quant, the three latest SRRK Change in Acquisitions & Divestments figures stand at $20.0 million (Q1 2026), $39.0 million (Q4 2025), and $78.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn -
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn -
3 Akari Therapeutics 989.71 Bn 989.71 Bn -
4 BeOne Medicines 471.62 Bn 466.83 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.97 Bn 114.72 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.98 Bn 61.22 Bn 3.31 Bn
7 Belite Bio 62.68 Bn 62.68 Bn -
8 Argenx Se 55.75 Bn 50.57 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn
10 Scholar Rock Holding 6.35 Bn 6.35 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 20.00 Mn
Mar 31, 2026 20.00 Mn
Dec 31, 2025 39.00 Mn
Dec 31, 2025 39.00 Mn
Sep 30, 2025 78.50 Mn
Sep 30, 2025 78.50 Mn
Jun 30, 2025 106.90 Mn
Jun 30, 2025 106.90 Mn
Mar 31, 2025 92.90 Mn
Mar 31, 2025 92.90 Mn
Dec 31, 2024 15.10 Mn
Dec 31, 2024 15.10 Mn
Sep 30, 2024 49.60 Mn
Sep 30, 2024 49.60 Mn
Jun 30, 2024 84.10 Mn
Jun 30, 2024 84.10 Mn
Mar 31, 2024 68.40 Mn
Mar 31, 2024 68.40 Mn
Dec 31, 2023 79.00 Mn
Dec 31, 2023 79.00 Mn